Immunomedics Company Profile

14:50 EST 16th December 2018 | BioPortfolio

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have recently licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock and lock methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We have transitioned our focus away from the development of diagnostic imaging products in order to accelerate the development of our therapeutic product candidates. Consistent with our de-emphasis on our diagnostic business, we no longer commercialize CEA-Scan®. LeukoScan® will continue to be manufactured and commercialized by us in territories where regulatory approvals have been granted. Furthermore, as of June 30, 2006, research and development into diagnostic product candidates was no longer a material portion of our business.


300 American Road
Morris Plains
United States of America


Phone: 973 605 8200
Fax: 973 605 8282

News Articles [38 Associated News Articles listed on BioPortfolio]

FDA Grants Priority Review to Immunomedics’ Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer

MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-dr...

Immunomedics and AZ/MedImmune enter trial collaboration

Immunomedics and AstraZeneca PLC/MedImmune LLC entered a trial collaboration to study the potential combination of Imfinzi (durvalumab) and sacituzumab govitecan as a front-line therapy for triple-neg...

Immunomedics nets $260.4mm through public offering

Immunomedics Inc. (monoclonal antibody-based therapies for cancer and autoimmune diseases) netted $260.4mm through a public offering of 11.5mm shares at $24. Funds will support continued development o...

Immunomedics, AstraZeneca collaborate in first-line triple-negative breast and urothelial cancers

Immunomedics has entered into a clinical collaboration with AstraZeneca and its global biologics research and development arm MedImmune in first-line triple-negative breast and urothelial cancers.

FDA accepts Immunomedics’ BLA and grants priority review for Sacituzumab Govitecan to treat metastatic triple-negative breast cancer

Immunomedics announced that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for filing and granted priority review for sacituzumab govitecan for the trea...

Priority Review for Immunomedics' ADC for TNBC

Immunomedics: Why This Biotech Could Go Crazy In 2019

Management tracks: E-Scape, Immunomedics

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune...


Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseas...

More Information about "Immunomedics" on BioPortfolio

We have published hundreds of Immunomedics news stories on BioPortfolio along with dozens of Immunomedics Clinical Trials and PubMed Articles about Immunomedics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomedics Companies in our database. You can also find out about relevant Immunomedics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Corporate Database Quicklinks

Searches Linking to this Company Record